Rock Creek Pharmaceuticals Reports on Inhibition of STAT 3 Activation, A Key Marker of Inflammation, In Phase I Clinical Trial in Europe
Westport Announces Closing of US$10 Million Registered Direct Offering and Concurrent Private Placement